These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32406289)

  • 41. An overview of the safety pharmacology society strategic plan.
    Pugsley MK; Authier S; Koerner JE; Redfern WS; Markgraf CG; Brabham T; Correll K; Soloviev MV; Botchway A; Engwall M; Traebert M; Valentin JP; Mow TJ; Greiter-Wilke A; Leishman DJ; Vargas HM
    J Pharmacol Toxicol Methods; 2018; 93():35-45. PubMed ID: 29330132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.
    Pollack PS; Chadwick KD; Smith DM; Billger M; Hirshberg B; Iqbal N; Boulton DW
    Cardiovasc Diabetol; 2017 Sep; 16(1):113. PubMed ID: 28903775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
    Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
    J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research.
    Van Deuren B; Van Ammel K; Somers Y; Cools F; Straetemans R; van der Linde HJ; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):11-23. PubMed ID: 19422925
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.
    Reynolds VL; Butler P; Abernathy MM; Aschenbrenner L; Best DD; Blank J; Crosby M; Custer L; Escobar PA; Kolaja K; Moggs J; Shuey D; Snyder C; Van Vleet T; Zhou J; Hart TK
    Regul Toxicol Pharmacol; 2020 Nov; 117():104746. PubMed ID: 32911461
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulatory Forum Opinion Piece
    Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
    Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Arrhythmogenic liability screening in cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies.
    Authier S; Pugsley MK; Troncy E; Curtis MJ
    J Pharmacol Toxicol Methods; 2010; 62(2):83-8. PubMed ID: 20601020
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety pharmacology methods and models in an evolving regulatory environment.
    Pugsley MK; de Korte T; Authier S; Huang H; Accardi MV; Curtis MJ
    J Pharmacol Toxicol Methods; 2017 Sep; 87():1-6. PubMed ID: 28461240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Response of safety pharmacologists to challenges arising from the rapidly evolving changes in the pharmaceutical industry.
    Bass AS; Pugsley MK; Sannajust F; Yoshinaga T; Valentin JP
    J Pharmacol Toxicol Methods; 2019; 98():106593. PubMed ID: 31158459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Technology and evaluation best practices for in vivo cardiovascular safety pharmacology studies].
    Ozaki H
    Nihon Yakurigaku Zasshi; 2021; 156(6):364-369. PubMed ID: 34719571
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The influence of hERG1a and hERG1b isoforms on drug safety screening in iPSC-CMs.
    Goversen B; Jonsson MK; van den Heuvel NH; Rijken R; Vos MA; van Veen TA; de Boer TP
    Prog Biophys Mol Biol; 2019 Dec; 149():86-98. PubMed ID: 30826123
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
    Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
    Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
    Cavero I; Holzgrefe H
    Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
    Pugsley MK; Curtis MJ; Hayes ES
    Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model.
    Morissette P; Nishida M; Trepakova E; Imredy J; Lagrutta A; Chaves A; Hoagland K; Hoe CM; Zrada MM; Travis JJ; Zingaro GJ; Gerenser P; Friedrichs G; Salata JJ
    J Pharmacol Toxicol Methods; 2013; 68(1):137-49. PubMed ID: 23649000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
    Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
    J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.
    Valentin JP; Guillon JM; Jenkinson S; Kadambi V; Ravikumar P; Roberts S; Rosenbrier-Ribeiro L; Schmidt F; Armstrong D
    J Pharmacol Toxicol Methods; 2018; 93():7-14. PubMed ID: 30030184
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations.
    Cavero I
    Expert Opin Drug Saf; 2009 Nov; 8(6):627-47. PubMed ID: 19998526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Innovation in safety pharmacology testing.
    Pugsley MK; Towart R; Authier S; Gallacher DJ; Curtis MJ
    J Pharmacol Toxicol Methods; 2011; 64(1):1-6. PubMed ID: 21640842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical to Clinical Translation of Hemodynamic Effects in Cardiovascular Safety Pharmacology Studies.
    Bhatt S; Northcott C; Wisialowski T; Li D; Steidl-Nichols J
    Toxicol Sci; 2019 May; 169(1):272-279. PubMed ID: 30726989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.